<DOC>
	<DOC>NCT02576457</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Severe sepsis or septic shock for at least 24 hours Documented or suspected infection Sepsisinduced immunosuppression Men and women â‰¥ 18 years old Autoimmune disease Organ transplant or bone marrow transplant Cancer treated in the past 6 months Hepatitis B virus (HBV) Infection Human Immunodeficiency Virus (HIV) infection and not on therapy prior to this episode of sepsis Hepatitis C virus (HCV) infection and still has virus (not cured)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>